CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for 3D Medicines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

3D Medicines Inc
No. 3 and No. 5, Laiyang Road
QINGDAO, SDG  China Ticker: 12441244
Business Summary
3D Medicines Inc is an investment holding company principally engaged in the research and development of oncology therapies. The Company's product pipeline includes small-molecule targeted drugs, single/bispecific antibodies, immune checkpoint inhibitors, and peptide vaccines, spanning multiple stages of cancer treatment. The Company's drug candidates include envafolimab, 3D189, 3D185, and 3D124. The Company is also engaged in the development of messenger ribonucleic acid (mRNA) products through mRNA research and development platform and oncology genomics big-data artificial intelligence (AI) analysis platform. The Company primarily conducts its businesses in domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer ZhaolongGong 60 6/25/2021 1/30/2018
Chief Financial Officer XiaohaoLu 39 1/12/2026 1/12/2026
Senior Director - Quality Management YueHe 45 8/1/2019 8/1/2019
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 183 (As of 6/30/2025)
Outstanding Shares: 258,177,000 (As of 6/30/2025)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026